Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5

PLoS One. 2014 Feb 3;9(2):e87448. doi: 10.1371/journal.pone.0087448. eCollection 2014.

Abstract

CCCTC-binding factor (CTCF) can both activate as well as inhibit transcription by forming chromatin loops between regulatory regions and promoters. In this regard, Ctcf binding on non-methylated DNA and its interaction with the Cohesin complex results in differential regulation of the H19/Igf2 locus. Similarly, a role for CTCF has been established in normal hematopoietic development; however its involvement in leukemia remains elusive. Here, we show that Ctcf binds to the imprinting control region of H19/Igf2 in AML blasts. We also demonstrate that Smarca5, which also associates with the Cohesin complex, facilitates Ctcf binding to its target sites on DNA. Furthermore, Smarca5 supports Ctcf functionally and is needed for enhancer-blocking effect at ICR. We next asked whether CTCF and SMARCA5 control the expression of key hematopoiesis regulators. In normally differentiating myeloid cells both CTCF and SMARCA5 together with members of the Cohesin complex are recruited to the SPI1 gene, a key hematopoiesis regulator and leukemia suppressor. Due to DNA methylation, CTCF binding to the SPI1 gene is blocked in AML blasts. Upon AZA-mediated DNA demethylation of human AML blasts, CTCF and SMARCA5 are recruited to the -14.4 Enhancer of SPI1 gene and block its expression. Our data provide new insight into complex SPI1 gene regulation now involving additional key epigenetic factors, CTCF and SMARCA5 that control PU.1 expression at the -14.4 Enhancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adenosine Triphosphatases / genetics*
  • Adenosine Triphosphatases / metabolism
  • Animals
  • Azacitidine / pharmacology
  • CCCTC-Binding Factor
  • Cell Line, Tumor
  • Chromosomal Proteins, Non-Histone / genetics*
  • Chromosomal Proteins, Non-Histone / metabolism
  • DNA Methylation / drug effects
  • Epigenesis, Genetic*
  • Gene Expression Regulation, Neoplastic
  • Genomic Imprinting
  • HeLa Cells
  • Humans
  • Immunoblotting
  • Insulin-Like Growth Factor II / genetics
  • Insulin-Like Growth Factor II / metabolism
  • K562 Cells
  • Leukemia, Erythroblastic, Acute / genetics
  • Leukemia, Erythroblastic, Acute / metabolism
  • Leukemia, Erythroblastic, Acute / pathology
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / metabolism
  • Leukemia, Myeloid / pathology
  • Microscopy, Confocal
  • Protein Binding
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins / metabolism
  • RNA Interference
  • RNA, Long Noncoding / genetics
  • RNA, Long Noncoding / metabolism
  • Repressor Proteins / genetics*
  • Repressor Proteins / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Trans-Activators / genetics*
  • Trans-Activators / metabolism

Substances

  • CCCTC-Binding Factor
  • CTCF protein, human
  • Chromosomal Proteins, Non-Histone
  • H19 long non-coding RNA
  • Proto-Oncogene Proteins
  • RNA, Long Noncoding
  • Repressor Proteins
  • Trans-Activators
  • proto-oncogene protein Spi-1
  • Insulin-Like Growth Factor II
  • Adenosine Triphosphatases
  • SMARCA5 protein, human
  • Azacitidine

Grants and funding

Primary grant support came from the following: GAUK 251070 45410 (MK) & GACR P305/12/1033 (TS). Institutional support came from the following: UNCE 204021, PRVOUK-­­ P24/LF1/3, SVV-­­2013-­­264507, CZ.1.05/1.1.00/02.0109., BIOCEV – Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (CZ.1.05/1.1.00/02.0109), from the European Regional Development Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.